Clinical trials: SGLT2 Inhibitor
Chronic Heart Failure With Reduced Systolic Function
Dapagliflozin Effect on Symptoms and Biomarkers in Patients With Heart Failure
The primary purpose of this study is to evaluate the impact of dapagliflozin, as compared with placebo, on heart failure disease-specific biomarkers, symptoms, health status, and quality of life in patients with chronic heart…
- Trial name
- DEFINE-HF (NCT02653482)
- Testing
- Dapagliflozin
- Where
- 25 sites in United States
- Volunteers
- 263 people
- Sponsor
- Saint Luke's Health System
Autosomal Dominant Polycystic Kidney Disease
Short-term Effects of an SGLT2 Inhibitor on Divalent Ions in Autosomal Dominant Polycystic Kidney Disease
This study aims to better understand electrolyte handling in patients with autosomal dominant polycystic kidney disease treated with the SGLT2 inhibitor Empagliflozin.
- Trial name
- SIDIA (NCT06435858)
- Testing
- Empagliflozin
- Where
- 2 sites in Switzerland
- Volunteers
- 16 people
- Sponsor
- Cantonal Hospital Graubuenden
Cardiovascular Diseases, Atherosclerosis
Ertugliflozin: Cardioprotective Effects on Epicardial Fat
The purpose of this study is to learn if Sodium-Glucose Cotransporter 2 inhibitor (SGLT2i) medications enhance beneficial properties of epicardial adipose tissue including metabolic flexibility, insulin sensitivity, decreased…
- Conditions
- Cardiovascular Diseases, Atherosclerosis, Type 2 Diabetes, Insulin Resistance
- Trial name
- NCT04167761
- Testing
- Ertugliflozin
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- Stanford University
Cardiovascular Diseases
Are the "Cardiac Benefits" of Empagliflozin Independent of Its Hypoglycemic Activity? (ATRU-4).
Purpose: The overall hypothesis of the study is that the benefits attained in the EMPA-OUTCOME were, at least in part, mediated by a glucose-independent mechanism.
- Trial name
- EMPA-TROPISM (NCT03485222)
- Testing
- Empagliflozin
- Where
- United States
- Volunteers
- 84 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Type 2 Diabetes Mellitus
Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period
Primary Objective: To demonstrate the superiority of the insulin glargine/lixisenatide fixed ratio combination (FRC) versus GLP-1 receptor agonist (GLP-1 RA) in hemoglobin A1c (HbA1c) change.
- Trial name
- LixiLan-G (NCT02787551)
- Testing
- Insulin glargine/lixisenatide fixed ratio combination, liraglutide, exenatide
- Where
- 124 sites in United States, Canada and 7 more
- Volunteers
- 514 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type II, Diabetes Mellitus, Non Insulin Dependent
An Efficacy, Safety, and Tolerability Study of Canagliflozin (JNJ-28431754) in Patients With Type 2 Diabetes
The purpose of this study is to evaluate the effectiveness, safety, and tolerability of JNJ-28431754 compared with placebo in patients with type 2 diabetes.
- Trial name
- NCT00642278
- Testing
- Canagliflozin (JNJ-28431754), Sitagliptin
- Where
- 78 sites in United States, Argentina and 11 more
- Volunteers
- 451 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Obesity Type 2 Diabetes Mellitus, Cardiovascular-kidney-metabolic Syndrome
Early GLP-1 Receptor Agonist and SGLT2 Inhibitor Add-On Strategies in Adults With Obesity, Type 2 Diabetes, Cardiovascular-Kidney-Metabolic Syndrome Stage 2-3, and Metabolic Dysfunction-Associated Steatotic Liver Disease
This retrospective observational target-trial emulation uses electronic health record data from the TriNetX US Collaborative Network to compare early treatment intensification strategies in adults with obesity, type 2 diabetes…
- Conditions
- Obesity Type 2 Diabetes Mellitus, Cardiovascular-kidney-metabolic Syndrome, Metabolic Dysfunction-Associated Steatotic Liver Disease
- Trial name
- NCT07566299
- Volunteers
- 118,805 people
- Sponsor
- Chung Shan Medical University
SLE, Lupus Nephritis
Cardio Renal Effects of SGLT2 Inhibitors Among Lupus Nephritis Patients
This study aims to assess sodium glucose linked transoprter inhibitors(SGT2i) role in regression of ongoing kidney and cardiac diseases among lupus nephritis patient either diabetic or non-diabetic under different…
- Conditions
- SLE, Lupus Nephritis, SGLT2 Inhibitors
- Trial name
- NCT05748925
- Testing
- dapagliflozin
- Where
- Egypt
- Volunteers
- 84 people
- Sponsor
- Mansoura University
Heart Failure, Type 2 Diabetes Mellitus
Ketones, Muscle Metabolism, and SGLT2 Inhibitors - Protocol 1
To examine the effect of an increase in plasma beta-hydroxy-butyrate (B-OH-B) levels, spanning the physiologic and pharmacologic range (+0.5, +2.0, and +5.0 mmol/L), on: (i) parameters of left ventricular (LV) systolic and…
- Trial name
- Protocol1 (NCT03560323)
- Testing
- Beta-hydroxy-butyrate
- Where
- 2 sites in United States
- Volunteers
- 41 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Diabetes Mellitus, Type 2
A Research Study in People With Type 2 Diabetes to Compare Two Types of Insulin: Insulin 287 and Insulin Glargine
This study compares insulin 287 (a possible new medicine) to insulin glargine (a medicine doctors can already prescribe) in people with type 2 diabetes.
- Trial name
- NCT03922750
- Testing
- Insulin icodec, Insulin glargine U100
- Where
- 38 sites in United States, Canada and 3 more
- Volunteers
- 154 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes, Overweight
Mechanisms of Weight Loss With SGLT2 Inhibition
The purpose of this study is to investigate the effect of canagliflozin, a medication approved by the FDA for the treatment of type 2 diabetes, on body weight and metabolism in people with type 2 diabetes who are overweight or…
- Conditions
- Type 2 Diabetes, Overweight, Obesity
- Trial name
- NCT02360774
- Testing
- Canagliflozin
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Beth Israel Deaconess Medical Center
Type 2 Diabetes Mellitus
Long-Term Safety Study of TA-7284 in Patients With Type 2 Diabetes Mellitus
The purpose of this study is to evaluate the safety and efficacy of TA-7284 as monotherapy or combination therapy with other oral anti-hyperglycaemic agent in Japanese patients with Type 2 diabetes mellitus on 52 weeks oral…
- Trial name
- NCT01387737
- Testing
- TA-7284-Low, TA-7284-High
- Where
- 7 sites in Japan
- Volunteers
- 1,299 people
- Sponsor
- Tanabe Pharma Corporation
Asymptomatic Hyperuricemia
A Study to Assess the Effect of Intensive Uric Acid (UA) Lowering Therapy With RDEA3170, Febuxostat, Dapagliflozin on Urinary Excretion of UA
This is a randomized, placebo controlled, double-blind, 2-way crossover study conducted on asymptomatic hyperuricemic patients. The core study consists of screening period, 2 treatment periods (verinurad + febuxostat +…
- Trial name
- NCT03316131
- Testing
- Verinurad, Febuxostat, Dapagliflozin
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Gout
Pharmacogenetics of SGLT2 Inhibitors
Sodium-dependent glucose transporter-2 (SGLT2) inhibitors are a new class of anti-diabetic drugs, which increase urinary glucose excretion thereby promoting weight loss and decreasing plasma glucose levels.
- Conditions
- Diabetes Mellitus, Gout, Hyperuricemia
- Trial name
- SGLT2iPGx (NCT02462421)
- Testing
- Canagliflozin
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
Type 2 Diabetes, Hypertension
Inhibition of Urinary Angiotensinogen and the Reduction of Blood Pressure by SGLT2 Inhibition in Patients With Type 2 Diabetes
To assess the effect of sodium-glucose cotransporter 2 (SGLT-2) inhibitors on blood pressure and urinary angiotensinogen. This is a cross over study design, where 40 subjects will receive Dapagliflozin for 6 weeks followed by…
- Trial name
- NCT02796170
- Testing
- Dapagliflozin
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Tulane University School of Medicine
Diabetes Mellitus, Type 2
An Efficacy Study of Canagliflozin or Sitagliptin to Determine Glucose Variability in Mexican Participants With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin
The main purpose of this study is to assess the effects of 4 weeks each of daily treatment with canagliflozin 300 milligram (mg) versus sitagliptin 100 mg as treatment adjuncts to metformin (at stable dosages) on intrapatient…
- Trial name
- COMETA (NCT03267576)
- Testing
- Canagliflozin 300 mg, Sitagliptin 100 mg, Metformin
- Where
- 5 sites in Mexico
- Volunteers
- 64 people
- Sponsor
- Janssen Research & Development, LLC
Type 2 Diabetes Mellitus
A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus
The main purpose of this study is to evaluate the efficacy and safety of the study drug known as dulaglutide when added to sodium-glucose co-transporter 2 (SGLT2) inhibitors in participants with type 2 diabetes mellitus.
- Trial name
- AWARD-10 (NCT02597049)
- Testing
- Dulaglutide, SGLT2 inhibitor, Metformin
- Where
- 41 sites in United States, Austria and 7 more
- Volunteers
- 424 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes Mellitus
An Efficacy, Safety, and Tolerability Study for TA-7284 in Patients With Type 2 Diabetes
The purpose of this study is to demonstrate the efficacy, safety, and tolerability of TA-7284 compared with placebo in patients with type 2 diabetes.
- Trial name
- NCT01022112
- Testing
- TA-7284-Low, TA-7284-Low-middle, TA-7284-High-middle
- Where
- 6 sites in Japan
- Volunteers
- 383 people
- Sponsor
- Tanabe Pharma Corporation
Obesity, Pre-diabetes
SGLT2 Inhibitor Effects on Inflammation and Heart Disease in Obesity Pilot
Obesity is associated with increased cardiometabolic disease risk due, in part, to heightened chronic inflammation arising from adipose tissue.
- Trial name
- NCT04907214
- Testing
- Empagliflozin 25 MG
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Vanderbilt University Medical Center
Type 2 Diabetes Mellitus
Efficacy and Safety Study of TA-7284 in Patients With Type 2 Diabetes
The purpose of this study is to evaluate the efficacy and safety of TA-7284 as monotherapy in patients with type 2 Diabetes for 24 weeks administration.
- Trial name
- NCT01413204
- Testing
- TA-7284 Low, TA-7284 High
- Where
- 5 sites in Japan
- Volunteers
- 272 people
- Sponsor
- Tanabe Pharma Corporation